

## Sodium zirconium cyclosilicate for the treatment of persistent hyperkalaemia in prevalent haemodialysis patients: Experience from clinical practice

**Mr Owain Brooks<sup>1,2</sup>**, Dr Ashraf Mikhail<sup>1</sup>, Professor Chris Brown<sup>1,2</sup>, Professor Mark Gumbleton<sup>2</sup>, Justine Jenkins<sup>2</sup>, Kaitlin Boyle<sup>2</sup>

<sup>1</sup>Department of Nephrology, Morriston Hospital, Swansea Bay University Health Board, Swansea, United Kingdom,

<sup>2</sup>School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom

**Background and Aims:** Sodium zirconium cyclosilicate (SZC) (Lokelma<sup>®</sup>) is a new oral potassium binder. In September 2019 the UK National Institute for Health and Care Excellence (NICE) did not recommend SZC for dialysis patients due to a lack of evidence [1]. The recent DIALIZE phase 3b randomised controlled trial concluded that SZC is an effective and well-tolerated treatment for hyperkalemia in haemodialysis (HD) patients [2]. We offer an insight into SZC treatment in HD patients with persistent hyperkalaemia in clinical practice.

**Method:** Adult prevalent HD patients prescribed SZC for persistent hyperkalaemia were included for analysis. The highest pre-dialysis serum potassium (sK<sup>+</sup>) values were recorded each month before (M-6 to M-1) and after (M1 to M5) SZC initiation. The primary efficacy measure was a reduction in sK<sup>+</sup> with SZC treatment.

**Results:** Sixteen patients (mean age 53.5 years, 56.3% male) were included for analysis. 43.8% (n=7) were diabetic. At the time of SZC initiation 43.8% (n=7) received HD via arteriovenous fistula, 12.4% (n=2) via arteriovenous graft and 43.8% (n=7) via tunnelled central venous catheter. The mean Urea Reduction Ratio [SD] was 68.5% [10.8] and the mean [SD] pre-HD bicarbonate was 22.8mmol/L [2.7]. The dialysate potassium prescription was 2mmol/L for 93.8% of patients (n=15) and 1mmol/L for 6.2% of patients (n=1). The mean [SD] achievement of prescribed dialysis hours over the previous 4 weeks was 93.5% [12.2]. 68.8% (n=11) had previous treatment with calcium polystyrene sulfonate and 12.5% (n=2) with patiromer. 18.8% (n=3) were currently prescribed a renin-angiotensin-aldosterone system inhibitor. 93.8% (n=15) had received dietetic advice. SZC starting doses ranged from 5g four times a week on non-dialysis days to 10g three times a day.

Mean [SD] sK<sup>+</sup> at month-1 (M-1) (immediate pre-treatment period) was 7.38mmol/L [0.31]. Mean [SD] sK<sup>+</sup> at month 1 (M1) was 6.37mmol/L [1.21]. The statistical difference between these groups was p=0.0023 (paired two-tailed T-test). Figure 1 includes mean maximum monthly pre-dialysis sK<sup>+</sup> from M-6 to M5.

SZC was stopped in two patients (after M1 with sK<sup>+</sup> 5.0mmol/L and after M4 with sK<sup>+</sup> 4.3mmol/L) as it was no longer clinically indicated. Two patients became non-compliant (clinician-suspected or confirmed by patient) with SZC after M2 (sK<sup>+</sup> 6.7mmol/L and sK<sup>+</sup> 6.4mmol/L). Subsequent sK<sup>+</sup> values would not reflect treatment with SZC in these patients. Figure 2 includes mean maximum monthly sK<sup>+</sup> for the 12 patients on SZC from M-3 to M5.

ANOVA and post-hoc Dunnett's tests were undertaken to compare SZC treatment months (M1, 2, 3, 4 and 5) to the immediate pre-treatment period (M-1). ANOVA was close to significance (p=0.058), with post-hoc corrected for multiple comparisons finding the data to be significant for M1 vs. M-1 (p=0.045) and M5 vs. M-1 (p=0.018). The same tests across M1 through M5 revealed no significant difference (p=0.968 ANOVA

and  $p=0.555$  Dunnett's), demonstrating that continued treatment with SZC to M5 did not result in a further decline in sK<sup>+</sup>.

Conclusion: Sodium zirconium cyclosilicate is effective in reducing pre-dialysis sK<sup>+</sup> in patients with moderate and severe hyperkalaemia undergoing haemodialysis in clinical practice.